A DOUBLE-BLIND-STUDY COMPARING A NEW NONERGOT, LONG-ACTING DOPAMINE AGONIST, CV 205-502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINEMIA

Twenty‐two hyperprolactinaemic women were randomly allocated to two groups and treated with bromocriptine or the new, non‐ergot, long‐acting dopamine agonist, CV 205‐502. The study was double‐blind for 6 months. Four patients in the bromocriptine group, but none in the CV 205‐502 group, discontinued the study because of adverse reactions. Adverse reactions in those receiving the new drug were milder and more transient than with bromocriptine. With once‐daily doses of 0.075 mg CV 205‐502, eight of 11 women achieved normal PRL concentrations after 8 weeks treatment (median (95% confidence limits), 352 (70‐987) mU/1) compared with two of nine receiving a divided daily dose of 5 mg bromocriptine (1802 (1205‐4438) mU/1) (P < 0.002). With doses of 0.075‐0.15 mg of CV 205‐502, 10 of 11 women achieved normal PRL concentrations at 24 weeks compared with three of the remaining seven women on doses of 5‐10 mg of bromocriptine. Regular menstrual bleeding was restored and galactorrhoea relieved in the majority of patients, with marginally greater efficacy with CV 205‐502. CV 205‐502 is highly effective for the long‐term treatment of hyperprolactinaemia. It is better tolerated than bromocriptine, is effective in a once‐daily dose, appears to be safe, and provides a valuable alternative to the dopamine agonist drugs in use today. Copyright © 1990, Wiley Blackwell. All rights reserved